Our data demonstrate the urgent dependence on more detailed studies of the immune response to SARS-CoV-2 vaccines in populations with underlying clinical conditions. == Data Availability Statement == The original contributions presented in the study are included in the article/Supplementary Material. release assay (IGRA). Antibody and T cell outcomes at this timepoint were compared to a group of 44 elderly patients not on dialysis, after immunization with Tozinameran. Median age of patients on chronic dialysis was 74.0 years (IQR 66.0, 82.0). The proportion of males was higher (69.4%) than females. Only 20/36 patients (55.6%, 95%CI: 38.2971.67) developed SARS-CoV-2-IgG antibodies at the first sampling, whereas 32/36 patients (88.9%, 95%CI: 73.0096.38) demonstrated IgG detection at the second sampling. In a longitudinal follow-up at ~10 weeks after the second dose, the proportion of dialysis patients reactive for anti-SARS-CoV-2-IgG decreased to 27/32 (84.37%, 95%CI: 66.4694.10) The proportion of anti-SARS-CoV-2 S1 IgA decreased from 33/36 (91.67%; 95%CI: 76.4197.82) at weeks 34 down to 19/32 (59.38; 95%CI: 40.7975.78). Compared to a cohort of vaccinees with comparable age but not on chronic dialysis seroconversion rates and antibody titers were significantly lower. SARS-CoV-2-specific T-cell responses 3 Rabbit Polyclonal to NSG2 weeks after second vaccination were detected in 21/31 vaccinated dialysis patients (67.7%, 95%CI: 48.5382.68) compared to 42/44 (93.3%, 95%CI: 76.4998.84) in controls of similar age. Patients on dialysis demonstrate a delayed, but robust immune response three to four weeks after the second dose, which indicates effective vaccination of this vulnerable group. However, the lower immunogenicity of Tozinameran in these patients needs further attention to develop potential countermeasures Medetomidine HCl such as an additional booster vaccination. Keywords:vaccination, COVID 19, dialysis, antibody response, SARS CoV 2 == Introduction == The coronavirus disease 2019 (COVID-19) pandemic has led to an urgent need for effective strategies, in particular for patients with kidney failure (KF), who have a high mortality (1). The COVID-19 vaccine Tozinameran (BioNTech/Pfizer) showed protection from 12 days after the first dose (2) and was demonstrated to be 95% effective in preventing COVID-19 (3). Robust SARS-CoV-2 antibody responses 7 days after the second dose were detected (4). However, patients with KF have an impaired response to vaccination (5) and the earliest reports on COVID-19 vaccination suggest that mRNA vaccines are immunogenic but some patients on dialysis do not seroconvert (68). Patients on kidney replacement therapy were excluded from previous trials. We investigated immunogenicity to COVID-19 vaccination with Tozinameran in Medetomidine HCl 43 patients with chronic kidney disease (CKD) stage 5 and provide Medetomidine HCl a longitudinal follow-up at 10 weeks after a second dose. == Methods == This study includes 43 patients on dialysis. Samples were taken at three different time points after a second dose of COVID-19 vaccine Tozinameran (BioNTech/Pfizer), which was given 21 days apart: 1st samples were taken on average 7.8 days (range 713, week 1), 2nd samples were taken on average 21.2 days (range 2026, weeks 34), and 3rd samples (longitudinal observation) were taken on average 64.7 days (range 6470, week 10) after the second dose. The study circulation diagram is usually shown inFigure 1. Of those two dialysis patients, who were excluded from analysis due to a known prior SARS-CoV-2 contamination, we obtained serum samples and marked these in reddish throughout the figures. In addition to serum samples, full blood (Li-Heparin) for T-cell assays was taken at the 2nd time point. At this time point sero-reactivity was compared to a group of 44 Tozinameran vaccinated persons of comparable age but not on dialysis from two ongoing observational cohort studies on immunogenicity of SARS-CoV-2 vaccines (9) and to 18 unvaccinated control patients on hemodialysis. == Physique 1. == Inclusion diagram dialysis patients. == Antibody Assessment and Screening of IFN- Release of SARS-CoV-2-Specific T Cells == Serum samples of vaccinated dialysis patients were analyzed for anti-SARS-CoV-2 IgG and IgA antibodies ~1, ~34, and ~10 weeks after the second dose by anti-SARS-CoV-2-S1 ELISA. ELISA was performed according to the manufacturers instructions (Euroimmun Medizinische Labordiagnostika AG, Lbeck, Germany). Briefly, serum samples were analyzed at a 1:101 dilution..